30,000 Shares in Omada Health, Inc. $OMDA Purchased by Eisler Capital Management Ltd.

Eisler Capital Management Ltd. purchased a new stake in shares of Omada Health, Inc. (NASDAQ:OMDA) in the 2nd quarter, Holdings Channel reports. The fund purchased 30,000 shares of the company’s stock, valued at approximately $545,000.

Several other large investors have also recently added to or reduced their stakes in the company. Emerald Advisers LLC acquired a new stake in shares of Omada Health during the second quarter worth approximately $5,089,000. Jennison Associates LLC bought a new stake in Omada Health during the 2nd quarter worth approximately $4,580,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Omada Health during the 2nd quarter valued at $2,950,000. Sanofi bought a new position in Omada Health in the 2nd quarter valued at $9,606,000. Finally, Teacher Retirement System of Texas acquired a new position in Omada Health in the second quarter worth $640,000.

Omada Health Stock Down 2.5%

Shares of NASDAQ:OMDA opened at $18.14 on Tuesday. The business’s 50 day simple moving average is $22.94. Omada Health, Inc. has a one year low of $14.14 and a one year high of $28.40.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on OMDA shares. Weiss Ratings restated a “sell (d)” rating on shares of Omada Health in a research note on Wednesday, October 8th. BMO Capital Markets initiated coverage on shares of Omada Health in a research report on Thursday, November 13th. They issued an “outperform” rating and a $27.00 price objective for the company. Evercore ISI boosted their target price on shares of Omada Health from $27.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Barclays increased their price target on shares of Omada Health from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Needham & Company LLC boosted their price objective on shares of Omada Health from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

About Omada Health

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.